

## S14-5 Safety of the psychotropic drugs in the light of Pharmaceutical Sciences and Clinical Pharmacy

○Takashi YOSHIO<sup>1</sup>

<sup>1</sup>Department of Clinical Pharmacy Faculty of Pharmaceutical Sciences, Toho University

It is necessary to consider many adverse effects in the treatment with psychotropic drugs. Side effects including extrapyramidal symptoms obstruct particularly in treatment with antipsychotics for schizophrenia. In the safe and effective use of the psychiatric drugs, the consideration of pharmacological characteristics for antipsychotics is necessary. In addition to the patient accepting the side effects to achieve therapeutic results, it is also important to continue therapy and measure the outcomes. Therefore, in the pharmaceutical care of drug therapy for schizophrenia, it is necessary to calculate the dosage of medication and to predict interaction or side effects of the medication. As a result of sharing information with healthcare personnel and family of the patient will lead to adherence to therapy with therapeutic efficacy and a decline in relapse. There have been reports of a two fold increase in deaths resulting from increased use of antipsychotics. Since the use of antipsychotic agents with polypharmacy influence patient's life, it should be carefully consider to be used. The results of a survey of prescription data by Psychiatric Clinical Pharmacy (PCP) Research Group showed a prescription rate of antipsychotic monotherapy is approximately 30% and the dosage is about 850mg in Japan. Moreover atypical antipsychotics which are recommended for low-dose monotherapy are often administered in combination. In this symposium, I describe an actual situation in psychotropic drug use based on a prescription survey data of the PCP Research Group. This survey approach is a method of examining safe and effective drugs use.